Compare CBSH & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | KYMR |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | 2008 | 2020 |
| Metric | CBSH | KYMR |
|---|---|---|
| Price | $56.21 | $110.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 24 |
| Target Price | $65.56 | ★ $139.35 |
| AVG Volume (30 Days) | ★ 822.8K | 743.5K |
| Earning Date | 10-20-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 4.39 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $12.02 | $167.19 |
| Revenue Next Year | $3.89 | N/A |
| P/E Ratio | $27.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.99 | $55.66 |
| 52 Week High | $60.92 | $130.05 |
| Indicator | CBSH | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 50.14 |
| Support Level | $49.89 | $110.64 |
| Resistance Level | $59.18 | $119.89 |
| Average True Range (ATR) | 0.95 | 4.97 |
| MACD | 0.29 | 0.57 |
| Stochastic Oscillator | 85.67 | 67.77 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. The company has three reportable segments. The Commercial segment provides lending, leasing, deposit, payment, and cash management services to business and government customers. The Retail Banking segment offers consumer deposits, consumer lending, mortgage banking, and debit and credit card services through its branch network. The Wealth segment provides trust, estate planning, brokerage, and investment management services to individual and institutional clients.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.